Alnylam and Ascletis Form Strategic Collaboration to Develop ALN-VSP, an RNAi Therapeutic for ...
12:10 EDT 12 Jul 2012 | LaMerie
Partnership is Focused on Developing ALN-VSP for Hepatocellular Carcinoma (HCC) in China, with Alnylam Retaining Rest-of-World Rights
Original Article: Alnylam and Ascletis Form Strategic Collaboration to Develop ALN-VSP, an RNAi Therapeutic for ...
More From BioPortfolio on "Alnylam and Ascletis Form Strategic Collaboration to Develop ALN-VSP, an RNAi Therapeutic for ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
